喘息に対するICS/LABAメンテナンス療法における吸入型コルチコステロイドの用量反応:体系的レビューとメタ解析
Jonathan H Noble1, Samantha Warhurst2, Ryan Cullen2
1Medical Research Institute of New Zealand, Wellington, New Zealand,; Victoria University of Wellington, Wellington, New Zealand,.
Chest
|September 5, 2025
まとめ
高用量の吸入用コルチコステロイド/長効β2-アゴニスト (ICS/LABA) 療法は,中量投与と比較して重度の喘息悪化を著しく減少させる. この発見は 喘息の管理と患者の治療結果を最適化するために 極めて重要です
科学分野:
- 肺科
- 薬理学について
- 臨床研究
背景:
- 高用量吸入用コルチコステロイド (ICS) は,低用量から中等用量以上の効果は限られている.
- 高用量のICSでは,全身的な副作用が懸念される.
- 長期作用ベータ2アゴニスト (LABA) と併用したICSの用量反応はよく定義されていません.
研究 の 目的:
- 持続的なICS/長作用ベータ2アゴニスト (LABA) 治療における吸入用コルチコステロイド (ICS) 投与量反応の関係を決定する.
- 喘息管理のためのICS/LABA吸入器内の異なるICS用量の有効性と安全性を評価する.
主な方法:
- ランダム化制御試験 (RCT) の体系的レビューとメタ解析.
- 高用量 (HD) と中用量 (MD),低用量 (LD) と低用量 (LD) とICS/LABAを比較した試験も含まれています.
- 主要アウトカム:重度の喘息悪化;次要アウトカム:喘息コントロール,スピロメトリー,重度の有害事象.
主要な成果:
- 高用量 (HD) ICS/ LABAは,中用量 (MD) ICS/ LABA (ペトのOR 0. 81; 95% CI 0. 67から0. 98) と比較して,重度の喘息の悪化を有意に減少させた.
- HDとMD ICS/ LABAの他の有効性または安全性に関する有意な差異はありません.
- HD と LD と MD と LD ICS/ LABA を比較した際には有意な差異は認められなかった.
結論:
- 維持用高用量ICS/LABA療法では,中量投与と比較して,重度の喘息悪化の確率は約20%低下します.
- この減少の臨床的関連性は,個々の患者の悪化リスクに依存する.
- 限られたデータがあるため,他のICS/LABA比較の用量反応関係を明らかにするためにさらなる研究が必要である.
関連する概念動画
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
382
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
382
COPD: Management Using Bronchodilators and Corticosteroids
300
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
300
Inhaled Medications
387
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
387
Drugs Used in Lower Respiratory Disorders: Overview
573
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
573
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists
374
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
374


